Hosted on MSN28m
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations SignificantlyBiotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback